Ma et al. developed pH-responsive hollow mesoporous silica nanoparticles (HMSNPs)-based drug/siRNA co-delivery vehicles that can deliver doxorubicin and siRNA against Bcl-2 protein simultaneously to targeted cancer cells [86]. The gene discussed is BCL2; the disease is cancer.